EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and safety of albendazole and praziquantel combination therapy for neurocysticercosis: A systematic review and meta-analysis

Teuku F. Duta, Meulu Alina, Ghina Tsurayya, Seyi S. Enitan, Grace A. John-Ugwuanya

Narra Review · 31.03.2025 · 1 (1)

DOI: 10.52225/narrarev.v1i1.3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Narra Review, online erschienen am 31.03.2025. Verfasst von Teuku F. Duta und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Albendazole and praziquantel, together with corticosteroids, are used in the treatment of active, symptomatic neurocysticercosis (NCC), either as mono- or combination therapy. Although monotherapy with either drug has been well-established, data on combination therapy are scare, including only a handful of studies with low patient numbers. Therefore, the aim of this meta-analysis was to determine the efficacy and safety of albendazole and praziquantel combination in the treatment of patients with active, symptomatic NCC. Randomized controlled trials examining combination therapy versus monotherapy in the treatment of people with active, symptomatic NCC were selected using the PRISMA framework from four databases (PubMed, Scopus, LILACS, Embase) up to May 2, 2023. Studies were included when they reported on cyst resolution in people with active, symptomatic NCC receiving albendazole and praziquantel combination therapy, along with the safety profiles. The quality of the study was assessed using the Risk of Bias tool version 2.0 and pooled data were meta-analyzed using fixed effects. A total of 1,466 papers were retrieved and screened, whereby only five studies were included (n=291 patients). The meta-analysis revealed that the albendazole and praziquantel combination was more effective in cyst resolution as compared to albendazole alone (n=255; odds ratio (OR): 3.29; 95% confidence interval (CI): 1.96–5.22; p

Zitieren

APA

Duta, T. F., Alina, M., Tsurayya, G., Enitan, S. S., & John-Ugwuanya, G. A. (2025). Efficacy and safety of albendazole and praziquantel combination therapy for neurocysticercosis: A systematic review and meta-analysis. Narra Review, 1(1). https://doi.org/10.52225/narrarev.v1i1.3

Vancouver

Duta TF, Alina M, Tsurayya G, Enitan SS, John-Ugwuanya GA. Efficacy and safety of albendazole and praziquantel combination therapy for neurocysticercosis: A systematic review and meta-analysis. Narra Review. 2025;1(1). doi:10.52225/narrarev.v1i1.3

BibTeX
@article{Duta2025,
  author = {Duta, Teuku F. and Alina, Meulu and Tsurayya, Ghina and Enitan, Seyi S. and John-Ugwuanya, Grace A.},
  title = {Efficacy and safety of albendazole and praziquantel combination therapy for neurocysticercosis: A systematic review and meta-analysis},
  journal = {Narra Review},
  year = {2025},
  volume = {1},
  number = {1},
  doi = {10.52225/narrarev.v1i1.3}
}
Kostenlos starten →